Skip to main content

Table 2 The efficacy analysis

From: Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Best Overall Response

Intention-to-treat population(n = 115)

Per-protocol population (N = 92a)

Complete remission, No. (%)

2 (1.73%)

2 (21.7%)

Partial remission, No. (%)

41 (35.65%)

41 (44.5%)

Stable disease, No. (%)

32 (27.82%)

32 (34.7%)

Disease progression No. (%)

17 (14.7%)

17 (18.4%)

ORRb, (95%CI)

37.4% (28.4–46.4%)

46.7% (36.3–57.1%)

DCRc, (95%CI)

65.2% (56.4–74.1%)

81.5% (73.4–89.6%)

  1. ORR Objective response rate, DCR Disease control rate; a Fourteen patients receiving less than 2 cycles of PLD and 7 patients without efficacy assessments after 2 cycles of PLD were excluded. Moreover,2 patients had a postbaseline efficacy assessment that could not be confirmed and thus were excluded; b Including patients with complete and partial responses; c Including patients with complete and partial responses and stable disease
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us